Clinical Trials Industry News More

  1. FDA Approves First Drug For Treatment Of Peripheral T-Cell Lymphoma 9/29/2009
    The U.S. Food and Drug Administration has approved Folotyn (pralatrexate), the first treatment for a form of cancer known as Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkins lymphoma.
  2. Vetter Inaugurates Comprehensive Site In Germany 9/29/2009
    The comprehensive Ravensburg Vetter South site was officially inaugurated on September 25. The past six years have seen Vetter invest significantly into the site, with a total area of some 80,000 m2 (862,000 ft2), that now includes state-of-the-art facilities for the aseptic filling and packaging of injectable drugs.
  3. ACR Image Metrix Completes Successful Second Year As Imaging CRO 9/24/2009
    ACR Image Metrix, an imaging contract research organization (CRO), exceeded its goals by initiating projects for over 30 pharmaceutical, biotechnology and medical device companies through its second full year of operation.
  4. Edmund Optics Releases New Catalog With Biotech Focus 9/22/2009
    Edmund Optics (EO), the premier provider of optical components, has released a catalog featuring product lines of specific interest for researchers and product developers working in the demanding biotech field.
  5. FDA Approves Vaccines For 2009 H1N1 Influenza Virus 9/17/2009
    The U.S. Food and Drug Administration announced recently that it has approved four vaccines against the 2009 H1N1 influenza virus. The vaccines will be distributed nationally after the initial lots become available, which is expected within the next four weeks.
  6. NIAID Launches 2009 H1N1 Influenza Vaccine Trial In Pregnant Women 9/14/2009
    The first trial testing a candidate 2009 H1N1 influenza vaccine in pregnant women is launching this week, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced recently.
  7. Millipore Presents: Innovations And Challenges For Sterilizing-Grade Technologies 9/8/2009
    September 24th Open House Event Recognizes Millipore’s 30 Years of Sterility Assurance
  8. Cytopia's CYT387 Receives FDA Clearance To Start US Clinical Trials 9/8/2009
    Cytopia Limited’s Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders.
  9. Bayer And Algeta Enter Global Agreement For Development And Commercialization Of Treatment For Bone Metastases In Cancer Patients 9/8/2009
    Bayer Schering Pharma AG, Germany has entered into a global agreement with Algeta ASA, Oslo, Norway for the development and commercialization of Alpharadin, a novel alpha-emitting radiopharmaceutical, based on radium-223. Alpharadin is currently being evaluated in a global Phase III trial for the treatment of bone metastases in symptomatic hormone-refractory prostate cancer (HRPC) patients.
  10. SynCo Bio Partners Enters The Japanese Market As It Signs Its First Agreement With A Japanese Pharmaceutical Company 9/2/2009
    SynCo Bio Partners B.V., the expert in long term GMP contract manufacturing of biopharmaceuticals announced recently that it has expanded its business into a new geographical market, with the signing of a contract to manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company.